Company intelligence / Profile preview

Nicovaper

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Nicovape is a healthcare company specializing in medical-grade nicotine delivery systems designed for smoking cessation. The company developed a proprietary vaping platform that provides a controlled, pharmacy-only alternative to traditional cigarettes and consumer-grade e-cigarettes. Nicovape's products are designed to meet pharmaceutical standards and are distributed through healthcare channels, primarily in Australia and New Zealand. In 2020, the company was acquired by Liber Pharmaceuticals to further its mission of providing regulated, therapeutic nicotine solutions.

Therapeutic areas: Psychiatry
Modalities: DeviceSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Nicovaper.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicovaper.

Explore the full profile